Demand More Insights From Your Liquid Biopsy


InterVenn Oncology is developing revolutionary tests using glycoproteomics to interrogate the body's immune response in a way never before possible. We are a CLIA-certified & CAP accredited laboratory.

“We exist today to equally and unequivocally improve patient care so no one is ever blindsided by disease.” — Aldo Carrascoso, CEO & Co-Founder | InterVenn Biosciences

Read Aldo's Vision

New biomarkers to drive next-generation precision medicine


We interrogate a complementary layer of biology for a deeper understanding of cancers. This enables an entirely new, vast repertoire of oncology biomarkers to drive next-generation precision medicine.

Highlights